What is the 13F Pro Quality Score for PRGO?

13F Pro ranks PERRIGO Co plc (PRGO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PRGO's current score at https://13fpro.ai/research/PRGO (free sign-up required for the full ranking).

Where does 13F Pro source PRGO data?

All PERRIGO Co plc fundamentals and ownership data come directly from SEC EDGAR. PERRIGO Co plc files with the SEC under CIK 1585364. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PRGO in?

PERRIGO Co plc (PRGO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PRGO research updated on 13F Pro?

PRGO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PERRIGO Co plc(PRGO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1585364 PRGO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PRGO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PERRIGO Co plc (PRGO), a Healthcare sector company. PRGO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), PERRIGO Co plc reports quarterly revenue of $969.2M, net income of $-398.6M, free cash flow of $-127.4M. Top institutional holders of PRGO by reported 13-F value include BlackRock,, Neuberger Berman Group, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PRGO trades on the NYSE exchange and files with the SEC under CIK 1585364. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PERRIGO Co plc directly from SEC EDGAR.

Revenue

Q1 2026

$969.2M

Net Income

Q1 2026

$-398.6M

Free Cash Flow

Q1 2026

$-127.4M

D/E Ratio

Q1 2026

1.45

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-8.6% YoY

$4.25BFY 2025

FY21 $4.14BFY22 $4.45BFY23 $4.66BFY25 $4.25B

Net Income

-11123.6% YoY

$-1.43BFY 2025

FY21 $-68.9MFY22 $-140.6MFY23 $-12.7MFY25 $-1.43B

Operating Income

-838.8% YoY

$-1.12BFY 2025

FY21 $410.4MFY22 $78.9MFY23 $151.9MFY25 $-1.12B

EPS (Diluted)

-11333.3% YoY

$-10.29FY 2025

FY21 $-0.52FY22 $-1.04FY23 $-0.09FY25 $-10.29

Total Assets

-21.0% YoY

$8.54BFY 2025

FY21 $10.43BFY22 $11.02BFY23 $10.81BFY25 $8.54B

Total Debt

-10.6% YoY

$3.64BFY 2025

FY21 $3.52BFY22 $4.11BFY23 $4.07BFY25 $3.64B

Op. Cash Flow

-41.2% YoY

$238.5MFY 2025

FY21 $156.3MFY22 $307.3MFY23 $405.5MFY25 $238.5M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$4.25B -8.6%	$4.66B +4.6%	$4.45B +7.6%	$4.14B +1.2%	$4.09B +5.6%	$3.87B
Net Income	$-1.43B -11123.6%	$-12.7M +91.0%	$-140.6M -104.1%	$-68.9M +57.6%	$-162.6M -211.3%	$146.1M
Operating Income	$-1.12B -838.8%	$151.9M +92.5%	$78.9M -80.8%	$410.4M +54.8%	$265.2M +51.8%	$174.7M
EPS (Diluted)	$-10.29 -11333.3%	$-0.09 +91.3%	$-1.04 -100.0%	$-0.52 +56.3%	$-1.19 -211.2%	$1.07
Total Assets	$8.54B -21.0%	$10.81B -1.9%	$11.02B +5.7%	$10.43B -9.3%	$11.49B +1.7%	$11.30B
Total Debt	$3.64B -10.6%	$4.07B -0.8%	$4.11B +16.6%	$3.52B -1.2%	$3.56B +5.8%	$3.37B
Operating Cash Flow	$238.5M -41.2%	$405.5M +32.0%	$307.3M +96.6%	$156.3M -75.4%	$636.2M +64.1%	$387.8M

AI Insight: PRGO Financial Trends

A massive $1.4B net loss in Q4 2025 followed by a $399M loss in Q1 2026 has destroyed over $1.6B in equity in two quarters, signaling deep impairment charges eroding the balance sheet.

• Equity collapsed from $4,446M in Q3 2025 to $2,499M in Q1 2026 — a $1.95B erosion in just two quarters.

• Operating income swung from $73M in Q3 2025 to -$1,287M in Q4 2025 and -$372M in Q1 2026, reflecting large non-cash write-downs.

• Total debt declined from $4,753M in Q3 2024 to roughly $3,632M–$3,640M across Q3–Q1 2026, showing some deleveraging progress.

• Revenue declined to $969M in Q1 2026, the lowest in the observed period, down from $1,138M in Q4 2024.

⚠ Operating cash flow turned negative at -$114M in Q1 2026 — first negative reading since Q1 2025 — raising near-term liquidity concerns.

⚠ With equity at $2,499M against $3,632M in debt, leverage has risen sharply; further impairments could breach debt covenants.

⚠ Revenue contraction in Q1 2026 to $969M warrants monitoring — any continued top-line erosion will pressure already thin operating income.

AI Insight: PRGO Ratio Trends

A massive Q4 2025 impairment-driven collapse (-116% OpMargin) has obliterated trailing returns, with leverage re-accelerating to 1.45x D/E.

• OpMargin swung from a recovery peak of 10.0% in Q4 2024 to -116.0% in Q4 2025, signaling a large non-cash charge.

• D/E ratio deteriorated from 0.82x in Q2–Q3 2025 back to 1.45x by Q1 2026, reversing a deleveraging trend.

• Q3 2025 briefly showed the only positive NPM (0.7%) and ROE (0.7%) in the entire dataset before Q4 reversed gains.

⚠ ROIC collapsed to -78.3% in Q4 2025 and remains deeply negative at -25.1% on a TTM basis — capital destruction is severe.

⚠ Whether Q4 2025 charges are truly one-off; sustained OpMargin below zero into Q1 2026 (-38.4%) suggests ongoing pressure.

⚠ D/E re-expansion to 1.45x alongside negative ROA limits financial flexibility if operating losses persist.

Get alerted when PRGO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PERRIGO Co plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PRGO

BlackRock, Inc.
$183.9M17,120,084 sh
Neuberger Berman Group LLC
$112.3M10,460,080 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$87.4M8,141,919 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$82.3M7,662,883 sh
STATE STREET CORP
$77.6M7,225,395 sh
DIMENSIONAL FUND ADVISORS LP
$70.5M6,567,616 sh
VANGUARD CAPITAL MANAGEMENT LLC
$66.7M6,209,537 sh
Invesco Ltd.
$50.6M4,711,783 sh
MILLENNIUM MANAGEMENT LLC
$46.0M4,279,731 sh
MENORA MIVTACHIM HOLDINGS LTD.
$41.6M3,872,000 sh

Fund	Value	Shares
BlackRock, Inc.	$183.9M	17,120,084
Neuberger Berman Group LLC	$112.3M	10,460,080
VANGUARD PORTFOLIO MANAGEMENT LLC	$87.4M	8,141,919
FULLER & THALER ASSET MANAGEMENT, INC.	$82.3M	7,662,883
STATE STREET CORP	$77.6M	7,225,395
DIMENSIONAL FUND ADVISORS LP	$70.5M	6,567,616
VANGUARD CAPITAL MANAGEMENT LLC	$66.7M	6,209,537
Invesco Ltd.	$50.6M	4,711,783
MILLENNIUM MANAGEMENT LLC	$46.0M	4,279,731
MENORA MIVTACHIM HOLDINGS LTD.	$41.6M	3,872,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PRGO on your watchlist

Track score changes the day PERRIGO Co plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PRGO a good stock to buy?

13F Pro's AI-powered analysis of PERRIGO Co plc (PRGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRGO are available on the PRGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PRGO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PERRIGO Co plc's investment landscape.